CN1520833A - 一种用于酒精性脂肪肝病的药物组合物 - Google Patents
一种用于酒精性脂肪肝病的药物组合物 Download PDFInfo
- Publication number
- CN1520833A CN1520833A CNA031020259A CN03102025A CN1520833A CN 1520833 A CN1520833 A CN 1520833A CN A031020259 A CNA031020259 A CN A031020259A CN 03102025 A CN03102025 A CN 03102025A CN 1520833 A CN1520833 A CN 1520833A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- dry extract
- metadoxine
- medicine
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title abstract description 4
- 208000010706 fatty liver disease Diseases 0.000 title description 11
- 208000004930 Fatty Liver Diseases 0.000 title description 8
- 206010019708 Hepatic steatosis Diseases 0.000 title description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 title description 8
- 239000003814 drug Substances 0.000 claims abstract description 41
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 7
- 208000026594 alcoholic fatty liver disease Diseases 0.000 abstract description 4
- 210000002381 plasma Anatomy 0.000 abstract description 4
- 230000035622 drinking Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 210000002700 urine Anatomy 0.000 abstract description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000002633 protecting effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- -1 metadoxine chemical compound Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 125000003724 cholesterol ester group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
对照组 | 治疗组 | P | |||
治疗前 | 治疗后 | 治疗前 | 治疗后 | ||
全血低切粘度 | 10.31±1.25△ | 9.48±1.35 | 10.32±1.27 | 8.87±1.30 | <0.01 |
全血高切粘度 | 7.30±0.42△ | 7.12±0.57 | 7.28±0.56 | 6.12±0.36 | <0.01 |
红细胞压积 | 0.048±0.042△ | 0.47±0.56 | 0.48±0.026 | 0.44±0.031 | <0.01 |
纤维蛋白原(g/L) | 4.77±0.84△ | 4.66±0.76 | 4.78±0.97 | 3.64±0.65 | <0.01 |
血浆粘度 | 1.85±0.08△ | 1.80±0.07 | 1.87±0.12 | 1.66±0.07 | <0.01 |
对照组 | 治疗组 | P | |||
治疗前 | 治疗后 | 治疗前 | 治疗后 | ||
甘油三脂(mmol/L) | 2.88±1.05△ | 1.76±0.59 | 2.88±1.07 | 1.60±0.52 | <0.01 |
胆固醇(mmol/L) | 6.07±1.01△ | 5.42±0.76 | 6.05±1.05 | 4.62±0.51 | <0.01 |
低密脂蛋白(mmol/L) | 4.98±0.76△ | 3.86±0.72 | 4.95±0.88 | 3.50±0.56 | <0.01 |
高密脂蛋白(mmol/L) | 1.14±0.20△ | 1.30±0.46 | 1.13±0.22 | 1.40±0.52 | <0.01 |
载脂蛋白Al(g/L) | 1.29±0.14△ | 1.29±0.24 | 1.29±0.17 | 1.26±0.12 | <0.01 |
载脂蛋白Bl(g/L) | 1.23±0.21△ | 0.98±0.56 | 1.23±0.21 | 0.92±0.15 | <0.01 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03102025 CN1246020C (zh) | 2003-01-28 | 2003-01-28 | 一种用于酒精性脂肪肝病的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03102025 CN1246020C (zh) | 2003-01-28 | 2003-01-28 | 一种用于酒精性脂肪肝病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1520833A true CN1520833A (zh) | 2004-08-18 |
CN1246020C CN1246020C (zh) | 2006-03-22 |
Family
ID=34281554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03102025 Expired - Fee Related CN1246020C (zh) | 2003-01-28 | 2003-01-28 | 一种用于酒精性脂肪肝病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1246020C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101610769B (zh) * | 2006-11-30 | 2011-09-21 | 首尔大学校产学协力团 | 包括美他多辛和大蒜油的医药组合物 |
CN104547911A (zh) * | 2014-12-30 | 2015-04-29 | 朱惊涛 | 一种治疗肝胃不和型酒精性肝病的中药制剂及制备方法 |
CN106822786A (zh) * | 2017-03-01 | 2017-06-13 | 潘鑫 | 治疗非酒精性脂肪肝病的中药颗粒剂 |
-
2003
- 2003-01-28 CN CN 03102025 patent/CN1246020C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101610769B (zh) * | 2006-11-30 | 2011-09-21 | 首尔大学校产学协力团 | 包括美他多辛和大蒜油的医药组合物 |
CN104547911A (zh) * | 2014-12-30 | 2015-04-29 | 朱惊涛 | 一种治疗肝胃不和型酒精性肝病的中药制剂及制备方法 |
CN106822786A (zh) * | 2017-03-01 | 2017-06-13 | 潘鑫 | 治疗非酒精性脂肪肝病的中药颗粒剂 |
Also Published As
Publication number | Publication date |
---|---|
CN1246020C (zh) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102370686B (zh) | 治疗慢性肝病的药物组合物及其应用 | |
CN1332700C (zh) | 一种用于治疗冠心病心绞痛的药物组合物 | |
CN1052164C (zh) | 一种治疗老年痴呆症的中药制剂 | |
CN1246020C (zh) | 一种用于酒精性脂肪肝病的药物组合物 | |
CN100518809C (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN112656802B (zh) | 白头翁皂苷b4在制备治疗多发性硬化药物中的应用 | |
CN1730090A (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
CN1682837A (zh) | 调节血脂的药物及其制备方法 | |
CN1224407C (zh) | 一种治疗糖尿病的药物组合物及其制备方法 | |
CN1159029C (zh) | 一种调脂药物及其制备方法 | |
CN100336540C (zh) | 一种治疗高脂血症的药物组合物及其制备方法 | |
CN101632829B (zh) | 一种抗肝纤维化的中药组合物及其制备方法与药物制剂 | |
CN1843460A (zh) | 降糖降脂降压、改善微循环及免疫的药剂及其制备方法 | |
CN1456309A (zh) | 一种降血脂和抗动脉粥样硬化的药物组合物及其制备方法、用途 | |
CN1386499A (zh) | 二苯乙烯酚苷类化合物在制备降血脂药物中的应用 | |
CN1250244C (zh) | 一种防治高脂血症的组合物 | |
CN1047944C (zh) | 一种治疗慢性肝炎的中药胶囊 | |
CN1279961C (zh) | 一种止咳祛痰中成药制剂及其制备方法 | |
CN108813564A (zh) | 对化学性肝损伤有保护功能的组合物及保健食品 | |
CN101850031A (zh) | 葛根异黄酮胶囊 | |
CN100340267C (zh) | 一种治疗脂肪肝的中药制剂 | |
CN1212150C (zh) | 治疗病毒性肝炎的药物及制备方法 | |
CN1054525C (zh) | 一种治疗“下消”型糖尿病的药物组合物 | |
CN1943658A (zh) | 一种治疗急慢性肝炎的中药组合物及其制备方法 | |
CN1823945A (zh) | 用于治疗脂肪肝的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEBEI MEDICAL UNIVERSITY Free format text: FORMER OWNER: WANG SHUYUE Effective date: 20060414 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060414 Address after: 050017 Hebei Medical University, 361 East Zhongshan Road, Hebei, Shijiazhuang Patentee after: Hebei Medical University Address before: 050017 School of pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, Hebei Patentee before: Wang Shuyue |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |